Monitor pricing and final share count when the offering prices; the overallotment option could add up to $747.5M total. The positive Q1 launch metrics and ACACIA-HCM data provide fundamental support, but near-term selling pressure from the offering may weigh on the stock.
Price Chart
Executive Summary
Cytokinetics filed a preliminary prospectus supplement for a $650M common stock offering, underwritten by Morgan Stanley, Goldman Sachs, J.P. Morgan, and Jefferies, with an option for an additional $97.5M. The filing comes on the same day as positive Q1 2026 results showing $4.8M in initial MYQORZO revenue and successful ACACIA-HCM trial results. Proceeds will fund the commercial launch and pipeline advancement, but the offering represents significant dilution.
Key Facts
- Aggregate public offering price of $650,000,000 for common stock
- Underwriters have 30-day option to purchase additional $97,500,000 in shares
- As of March 31, 2026, net tangible book deficit was $(826.6) million, or $(6.65) per share
- 124,237,823 shares outstanding as of March 31, 2026
- Proceeds intended for MYQORZO commercial launch, pipeline advancement, and general corporate purposes
- Directors and executive officers subject to 45-day lock-up agreements
- Q1 2026 MYQORZO net product revenue of $4.8 million from initial partial quarter
- Cash and investments of approximately $1.1 billion as of March 31, 2026
Financial Impact
$650 million offering represents approximately 8% dilution at current market cap, with proceeds strengthening cash position for commercialization
Risk Factors
- Significant dilution to existing shareholders
- Execution risk in commercial launch of MYQORZO
- Potential downward price pressure from at-the-market sales by underwriters
- Continued cash burn from R&D and commercialization activities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001193125-26-206626 |
| Document: 0001193125-26-206626-index-headers.html | 0001193125-26-206626 |
| Document: 0001193125-26-206626-index.html | 0001193125-26-206626 |
| Document: 0001193125-26-206626.txt | 0001193125-26-206626 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | Insider Cluster | $69.31 $67.59 | ▲ +2.48% | ▲ +4.59% | $65.60 (+5.35%) |
Sep 11, 2026 20d ago | Insider Cluster | $72.45 $67.56 | ▼ −6.75% | ▼ −6.86% | $65.60 (−9.45%) |
Sep 1, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 31, 2026 4w ago | Insider Cluster | $71.40 $74.11 | ▲ +3.80% | ▲ +3.71% | $65.60 (−8.12%) |
Aug 29, 2026 4w ago | Press Release | $70.91 $75.35 | ▲ +6.26% | ▲ +6.40% | $65.60 (−7.49%) |
Aug 28, 2026 5w ago | 8-K | $72.09 $72.72 | ▲ +0.87% | ▲ +0.76% | $65.60 (−9.00%) |
Jul 30, 2026 9w ago | Insider Cluster | $80.42 $81.37 | ▲ +1.18% | ▼ −2.44% | $65.60 (−18.43%) |
Jul 27, 2026 9w ago | Insider Cluster | $80.62 $77.13 | ▼ −4.33% | ▼ −5.40% | $65.60 (−18.63%) |
Jul 23, 2026 10w ago | Press Release | $80.74 $80.42 | ▼ −0.40% | ▼ −0.77% | $65.60 (−18.75%) |
Jul 14, 2026 11w ago | Insider Cluster | $81.93 $79.11 | ▼ −3.44% | ▼ −2.15% | $65.60 (−19.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access